Supportive Care in Oncology: Current and Future Trends
Sponsored by: GlobalData
- Cancer Cachexia
- Oral Mucositis
- Supportive Care
Date: 31 January
Days to go: 8
Time: 4PM London/11AM New York
Insights and KOL Views on CINV, Cancer Cachexia, Oral Mucositis, Bone Metastasis, CIN and CIA
Supportive care in oncology is a broad term that encompasses indications that are either a symptom of a patient’s cancer or a side effect of cancer treatment. It is a traditionally overlooked field, but recognition of its importance is growing across the 7MM and will continue to do so in the next five to ten years according to KOLs.
This webinar focuses on six prominent cancer supportive care indications: chemotherapy-induced nausea and vomiting (CINV), cancer cachexia, oral mucositis, bone metastases, chemotherapy-induced neutropenia (CIN), and chemotherapy-induced anemia (CIA).
The current landscapes for, as well as KOL views towards these indications, within the seven major markets of the US, 5EU and Japan will be presented. An analysis of how these landscapes will evolve in the future will be highlighted through a discussion of pipeline trends, the key unmet needs and opportunities in each indication, and clinical trial design considerations and challenges.
Analyst, Oncology and Hematology
Arshad Ahad is an Oncology and Hematology Analyst at GlobalData in London. Prior to joining GlobalData Healthcare, Arshad gained three years of experience across business intelligence firms - working at GBI Research as a Life Sciences Analyst, and Visiongain as a Senior Pharmaceutical Industry Analyst. During that time he authored a varied catalogue of pharmaceutical market research reports across multiple therapy areas. Prior to becoming an analyst, Arshad also worked at TPP, an electronic health record provider, and completed an internship with consumer goods and OTC drugs provider, Reckitt Benckiser. Arshad graduated top of his class with First Class Honors in Biomedical Sciences with Business (BSc), from The University of Newcastle. There he also worked with a university spin-out company, PB Bioscience, on a project to develop personalized nutrition based on genetics, for his dissertation.
Director of Oncology and Hematology
Fern Barkalow, PhD, has nearly 20 years of experience in the biopharmaceutical industry, as well as a research background in the molecular mechanisms of inflammation and metastasis. After leaving the lab bench, Fern moved into the database group at Incyte Pharmaceuticals, where she helped develop the Proteome BioKnowledge Library, and led a cross-functional team tasked with creating databases covering diseases and molecular interactions. She then joined the Medical Affairs group at Millennium Pharmaceuticals and managed medical writing projects involving clinical trials results for oncology drugs. Most recently, Fern was Associate Director of the Oncology team at Citeline, where she participated in developing and managing the Trialtrove database and interacted with clients through the research support service and custom analytics projects. Fern holds a PhD in Microbiology from The University of Medicine and Dentistry of New Jersey, and was a postdoctoral fellow in Molecular Biology at Princeton University and in Pathology at Brigham and Women's Hospital in Boston.
Key Learning Objectives
- Gain KOL insight into the past, present, and future trends in supportive care in oncology within their countries
- Understand the current competitive landscapes for six prominent supportive care indications: CINV, cancer cachexia, oral mucositis, bone metastases, CIN, and CIA
- Identify the unmet needs and opportunities in each indication
- Gain insight into pipeline trends, R&D strategies, and clinical trial design considerations within these indications
- Managers/Senior Managers/Associate Directors/Directors of Market Research
- Business Insights
- Market Intelligence
- Strategic Insights
- Pipeline Management
- Competitive Strategy
- Customer Insights
- Heads of Research and Development
- Heads of Product Planning and Marketing
- Brand Managers